325 related articles for article (PubMed ID: 27722855)
1. Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.
Greenberg WM; Citrome L
Clin Pharmacokinet; 2017 May; 56(5):493-503. PubMed ID: 27722855
[TBL] [Abstract][Full Text] [Related]
2. Lurasidone: an antipsychotic with antidepressant effects in bipolar depression?
Keks NA; Hope J; Castle D
Australas Psychiatry; 2016 Jun; 24(3):289-91. PubMed ID: 27036122
[TBL] [Abstract][Full Text] [Related]
3. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile.
Jaeschke RR; Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Styczeń K; Datka W
Pharmacol Rep; 2016 Aug; 68(4):748-55. PubMed ID: 27203278
[TBL] [Abstract][Full Text] [Related]
4. Lurasidone in the treatment of schizophrenia: a critical evaluation.
Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
[TBL] [Abstract][Full Text] [Related]
5. Lurasidone: an atypical antipsychotic for schizophrenia.
Risbood V; Lee JR; Roche-Desilets J; Fuller MA
Ann Pharmacother; 2012; 46(7-8):1033-46. PubMed ID: 22828971
[TBL] [Abstract][Full Text] [Related]
6. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
Citrome L
Clin Schizophr Relat Psychoses; 2011 Jan; 4(4):251-7. PubMed ID: 21177242
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Lurasidone in Children and Adolescents: Recommendations for Clinical Management and Future Research.
Amerio A; Giacomini C; Fusar-Poli L; Aguglia A; Costanza A; Serafini G; Aguglia E; Amore M
Curr Pharm Des; 2021; 27(39):4062-4069. PubMed ID: 34348620
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
9. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials.
Zheng W; Cai DB; Yang XH; Li L; Zhang QE; Ng CH; Ungvari GS; Li XB; Ning YP; Xiang YT
J Psychiatr Res; 2018 Aug; 103():244-251. PubMed ID: 29906709
[TBL] [Abstract][Full Text] [Related]
10. Lurasidone in schizophrenia: new information about dosage and place in therapy.
Citrome L
Adv Ther; 2012 Oct; 29(10):815-25. PubMed ID: 23001538
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders.
Findling RL; Goldman R; Chiu YY; Silva R; Jin F; Pikalov A; Loebel A
Clin Ther; 2015 Dec; 37(12):2788-97. PubMed ID: 26631428
[TBL] [Abstract][Full Text] [Related]
12. Lurasidone for schizophrenia.
Drug Ther Bull; 2015 Mar; 53(3):30-2. PubMed ID: 25765597
[TBL] [Abstract][Full Text] [Related]
13. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
[TBL] [Abstract][Full Text] [Related]
14. A review of published evidence reporting on the efficacy and pharmacology of lurasidone.
McIntyre RS; Cha DS; Alsuwaidan M; McIntosh D; Powell AM; Jerrell JM
Expert Opin Pharmacother; 2012 Aug; 13(11):1653-9. PubMed ID: 22559286
[TBL] [Abstract][Full Text] [Related]
15. How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia.
Macaluso M; Kazanchi H; Preskorn SH
Expert Opin Drug Metab Toxicol; 2015; 11(8):1317-27. PubMed ID: 26173973
[TBL] [Abstract][Full Text] [Related]
16. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders.
Pompili M; Verzura C; Trovini G; Buscajoni A; Falcone G; Naim S; Nardella A; Sorice S; Baldessarini RJ; Girardi P
Expert Opin Drug Saf; 2018 Feb; 17(2):197-205. PubMed ID: 28902525
[TBL] [Abstract][Full Text] [Related]
17. Lurasidone in Children and Adolescents: Systematic Review and Case Report.
Channing J; Mitchell M; Cortese S
J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):428-436. PubMed ID: 30004236
[TBL] [Abstract][Full Text] [Related]
18. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population.
Guay DR
Consult Pharm; 2011 Aug; 26(8):579-82. PubMed ID: 21840821
[TBL] [Abstract][Full Text] [Related]
19. A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy.
Naccarato M; Hall E; Wai A; Ostrowski M; Carvalhal A
Antivir Ther; 2016; 21(8):735-738. PubMed ID: 27328703
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone as a potential therapy for bipolar disorder.
Woo YS; Wang HR; Bahk WM
Neuropsychiatr Dis Treat; 2013; 9():1521-9. PubMed ID: 24143101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
